Becton, Dickinson and Company (BD) has acquired self-adhesive surgical sealant films developer Tissuemed for an undisclosed amount.

Tissuemed’s sealant technology, Tissuepatch, binds to tissues to prevent leaks from surgical incisions and can be used to control internal bleeding.

With a thin, flexible and transparent composition, the technology helps clinicians to seal sutured or stapled tissues against leakage of air, blood and other fluids, including cerebrospinal fluid (CSF), after surgical procedures.

It is said to be ideally suited for a range of surgical sealant applications.

BD stated that the acquisition of Tissuemed expands its offerings for surgeons outside the US and across the globe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It also complements the company’s core portfolio by adding Tissuemed’s surgical sealant to its suite of biosurgery products, which are already being used in the operating room.

BD surgery president Kevin Kelly said: “This advanced sealant serves as a strategic complement to the BD products used in the operating room today, providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions.

“Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”

With significant growth plans for the next five to ten years, the company plans to use its clinical expertise to advance the sealant technology category.

In October, BD partnered with the US Biomedical Advanced Research and Development Authority (BARDA) to develop a range of Covid-19 combination diagnostic tests.

As part of the partnership, BARDA agreed to provide initial funding of $24.7m to BD, which could be extended up to $40.3m.